A Comparison of Combivent® UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) in a Double-Blind Efficacy and Safety Study in Asthmatic Children With Severe Acute Exacerbation
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 10
- 主要终点
- The proportion of patients showing improvement in asthma severity scores from severe at baseline to mild at the end of the treatment
研究概览
简要总结
To compare the bronchodilator efficacy of ipratropium plus salbutamol (Combivent) with salbutamol alone given every 20 minutes for three doses in asthmatic children with severe acute exacerbation
详细描述
A Comparison of Ipratropium 500mcg and salbutamol 2.5mg (Combivent UDV) and salbutamol UDV alone (2.5mg) in a Double-blind, Efficacy and Safety Study in Asthmatic Children with Severe Acute Exacerbation
Study Hypothesis:
Several studies, including a study conducted in an emergency room setting, demonstrated that the addition of ipratropium bromide, an anticholinergic drug, to standard salbutamol therapy significantly improves pulmonary function as compared to salbutamol alone.
Comparison(s):
Ipratropium bromide 500 mcg plus salbutamol 2.5mg (Combivent) vs salbutamol (2.5mg) alone given every 20 minutes for 3 doses
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 2 Years 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients must have a known history of asthma and present to the hospital/clinic with severe acute exacerbation.
- •Male or female patients 2 to 10 years of age.
- •Parents or legal guardians of patients must sign an Informed Consent Form prior to participation in the trial.
排除标准
- •Patients with known or suspected hypersensitivity to study drugs
- •Patients with medical condition that would contraindicate the use of beta2-adrenergic or anticholinergic medications
- •Patients with first wheezing episode only
- •Prior intubation for asthma for more than 24 hours
- •Patients who used ipratropium within six hours prior to consultation
- •Patients with concurrent stridor or possible presence of intra-thoracic foreign body
- •Patients with disease known to have chronic effect on respiratory function ( e.g., cystic fibrosis or cardiac disease)
- •Patients requiring immediate resuscitation or airway intervention
- •With psychiatric disease or psychosocial problems
- •Patients on other investigational drugs or have used any other investigational drugs within the past month
结局指标
主要结局
The proportion of patients showing improvement in asthma severity scores from severe at baseline to mild at the end of the treatment
次要结局
- Change in asthma severity scores from baseline to end of treatment; number of patients needing hospitalization; number of rescue medications; oxygen saturation, number of discharged patients revisiting the ER/doctors clinic